Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Daniel Kreutz (NPI 1275789877)

Field	Value
Entity Type	Individual
Organization	Daniel Kreutz
Address	3645 S Rome St Ste 201
City	Gilbert
State	AZ
ZIP	85297
Taxonomy	Rheumatology Physician
NPI Enumerated	August 14, 2008

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused rheumatology practice: lifetime Medicare revenue is $2.8M and Medicaid revenue is none (no Medicaid billing on file), indicating an essentially single‑payer footprint in available claims data. The NPI was enumerated 2008-08-14 (~18 years ago), consistent with an established solo or small-group clinical presence rather than a newly opened practice.

Revenue concentration is high and biologics-driven: the precomputed top 3 Medicare codes by revenue account for 48.1% of the provider's total Medicare revenue, with J0129 ($538.8K, 19.9%), J1602 ($414.1K, 15.3%), and J0897 ($351K, 13.0%) comprising nearly half of all Medicare receipts. These three codes are all injectable biologic or specialty drug administrations, signaling that in-office or infusion-administered medications are the core revenue drivers.

Service-line implications from the CPT/HCPCS mix point to an infusion/biologics administration model combined with outpatient rheumatology care: high-volume biologic drug codes such as J0129, J1602, J0897, J1745 and biosimilar Q5104 appear alongside E/M codes (99214, 99215, 99205) and chemotherapy/infusion administration codes (96413, 96401, 96415). This combination suggests the practice provides both procedural infusion services and longitudinal rheumatologic management requiring routine lab monitoring.

Competitive standing for the top biologics is mixed: J1602 ranks #72 of 1041 providers nationally (93th percentile) and J0129 ranks #208 of 1221 providers nationally (83th percentile), indicating above‑median participation but not dominance for these drugs; by contrast J0897 ranks #305 of 10057 providers nationally (97th percentile) and is described as notably above typical national volume, which implies unusually high denosumab administration relative to most peers.

Several utilization signals are statistical outliers for office and infusion activity: 99214 ranks #2298 of 479517 providers nationally (100th percentile; extreme outlier, far above typical national volume), 96413 ranks #118 of 7514 providers nationally (98th percentile; extreme outlier, far above typical national volume), and 99205 ranks #444 of 66257 providers nationally (99th percentile; extreme outlier, far above typical national volume). These outlier E/M and infusion administration rankings reinforce that this provider bills both frequent, higher‑level office visits and high-volume infusion or chemo‑administration sessions compared with national peers.

The presence and ranking of infliximab and biosimilar codes (J1745 $238.3K, Q5104 $127.4K) alongside rituximab (J9312 $301.8K) and certolizumab (J0717 $143.2K) indicate a therapeutically diverse biologics portfolio—both branded and biosimilar infliximab appear in the top codes—suggesting the practice treats a range of autoimmune and inflammatory conditions and may switch between branded and biosimilar products depending on clinical or payer factors.

Routine monitoring and ancillary services support the infusion model: frequent lab and specimen codes such as 80053 (1.4K claims, $13.8K), 36415 (1.6K claims, $12.5K), 85025 (1.3K claims, $10K), and 86140 (821 claims, $4.1K) appear at high national percentiles, reflecting consistent pre‑infusion and disease‑management testing typical for rheumatology patients on biologics. These lab patterns are consistent with ongoing disease monitoring and infusion safety workflows.

From a payer strategy and contracting perspective, the lack of any Medicaid billing (none below) means this provider’s negotiated rates and utilization patterns will be visible only to Medicare and commercial payers in available claims; payers evaluating network adequacy or specialty infusion capacity should treat this entity as Medicare‑centric with substantial in-office infusion throughput driven by a small set of high-revenue biologic codes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

55 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	16,330	$30	$538.8K
J1602	Injection, golimumab, 1 mg, for intravenous use	41,410	$10	$414.1K
J0897	Injection, denosumab, 1 mg	19,500	$20	$351K
J9312	Injection, rituximab, 10 mg	4,790	$60	$301.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	9,530	$30	$238.3K
J3111	Injection, romosozumab-aqqg, 1 mg	27,510	$10	$192.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,720	$90	$153.3K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	35,800	$1	$143.2K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	4,390	$30	$127.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	900	$100	$89.4K

Showing 1–10 of 55

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 55 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Daniel Kreutz — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

55 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	9	30	14,700	$30	$494.5K
J1602	7	30	24,040	$10	$316.2K
J0717	11	20	36,100	$1	$246.6K
J9312	2	20	3,250	$60	$212.6K
J3111	11	40	19,530	$10	$178.8K
J0897	20	260	2,940	$20	$115.6K
Q5104	2	10	3,720	$30	$108.7K
J1745	2	40	2,980	$30	$103.9K
86235	4	20	130	$20	$59.5K
83970	68	130	80	$40	$33K

Showing 1–10 of 55

Related Providers

Other providers that share a Tax Identification Number (TIN) with Daniel Kreutz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Arizona Arthritis & Rheumatology Associates P C	AZ	Rheumatology Physician	$0	$11.2M
Nehad Soloman	AZ	Rheumatology Physician	$5.1M	$0
Alexander Hu	AZ	Internal Medicine Physician	$3.8M	$0
Areena Swarup	AZ	Rheumatology Physician	$3.6M	$0
Saima Chohan	AZ	Rheumatology Physician	$3.5M	$0
Nikila Kumar	AZ	Rheumatology Physician	$3M	$0
John Tesser	AZ	Rheumatology Physician	$3M	$0
Mona Amin	AZ	Rheumatology Physician	$2.7M	$0
Joonhee Lim	AZ	Rheumatology Physician	$2.3M	$0
Andrew Sharobeem	AZ	Rheumatology Physician	$2.3M	$0

Nearby Providers

Other providers in the same ZIP code as Daniel Kreutz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Warner Park Surgery Center LLC	AZ	Ambulatory Surgical Clinic/Center	$964.6K	$694.3K
Zaki Lababidi	AZ	Cardiovascular Disease Physician	$1.3M	$0
Naveen Kumar	AZ	Otolaryngology/Facial Plastic Surgery Physician	$1.1M	$0
Surgcenter Chandler, LLC	AZ	Ambulatory Surgical Clinic/Center	$1.1M	$0
Ortho Arizona Surgery Center Gilbert, LLC	AZ	Ambulatory Surgical Clinic/Center	$834.1K	$0
Ocotillo Surgery Center LLC	AZ	Ambulatory Surgical Clinic/Center	$606.2K	$222.1K
Khaled Albasha	AZ	Cardiovascular Disease Physician	$608.2K	$0
Daniel Condie	AZ	Dermatology Physician	$552.8K	$0
Devendra Wadwekar	AZ	Endocrinology, Diabetes & Metabolism Physician	$528.7K	$0
Ahdev Kuppusamy	AZ	Interventional Pain Medicine Physician	$374.3K	$0

Daniel Kreutz — Billing Profile & Reimbursement Data

Sign up for Daniel Kreutz — Billing Profile & Reimbursement Data policy alerts

Daniel Kreutz — Billing Profile & Reimbursement Data

Sign up for Daniel Kreutz — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References